Severe Asthma Management
Publication Date: October 1, 2019
Key Points
Key Points
Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.
Treatment
...Treatmen...
...Table 1. Recommend...
...ti-IL-5 strategy as add-on therapy for adult pat...
...that a blood eosinophil cut-point ≥150 µL...
...a blood eosinophil cut-off ≥260 µL−1 to...
...using a FENO cut-off ≥19.5 ppb to identi...
...r children, adolescents and adults with severe ast...
...suggest a trial of macrolide treatment to reduce...
...suggest against the use of chronic macroli...
...t dupilumab as add-on therapy for adult patients...
...e 2. Monoclonal Antibodies for Severe AsthmaHa...